Latest Developments in Global Mastopexy Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Mastopexy Market

  • Pharmaceutical
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In December 2024, Mentor Worldwide LLC announced that the U.S. Food and Drug Administration (FDA) had approved MENTOR™ MemoryGel™ Enhance Breast Implants for primary and revision breast reconstruction surgery in women following mastectomy. Mentor plans to officially launch the MemoryGel™ Enhance Breast Implants commercially in the U.S. starting in mid-2025
  • In October 2024, Galderma announced the continuation of its collaboration with the National Breast Cancer Foundation (NBCF), Inc., celebrating a decade of empowering and supporting individuals affected by breast cancer. This ongoing partnership aims to assist those impacted by breast cancer, helping them not only survive but thrive. Through the provision of innovative aesthetic solutions, the collaboration seeks to help individuals regain their confidence and embrace life with renewed vitality
  • In September 2024, POLYTECH launched Opticon Plus, a new addition to its extensive portfolio. Renowned for offering the widest variety of products in the industry, POLYTECH now includes this innovative implant, which fills the gap between their anatomical forms, Replicon® and Opticon. The Opticon Plus provides surgeons with an option that features a base shape between the round Replicon® base and the standard Opticon short oval base
  • In June 2023, Sientra, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance for its novel, patented AlloX2 Pro Tissue Expander. This breakthrough innovation enables the AlloX2 Pro to be labeled as MRI-conditional, making it the first tissue expander in the United States approved for use in patients undergoing magnetic resonance imaging, an essential screening tool for breast reconstruction
  • In August 2020, Lumenis Ltd. unveiled its latest innovation, the NuEra Tight with FocalRF technology. This platform represents a significant advancement in personalized non-invasive RF body treatments, designed to address the specific needs of each patient. The NuEra Tight with FocalRF technology was developed to offer customized body treatments that are tailored to an individual’s unique requirements

Frequently Asked Questions